Core Viewpoint - Metagenomi, Inc. is set to present at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its commitment to developing curative therapeutics through its proprietary gene editing toolbox [1]. Company Overview - Metagenomi is a precision genetic medicines company focused on curative therapeutics using a comprehensive metagenomics-derived toolbox [3]. - The company utilizes metagenomics to explore four billion years of microbial evolution, aiming to discover novel editing tools for correcting genetic mutations across the genome [3]. - Its genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and CAST [3]. - Metagenomi believes its diverse and modular toolbox allows access to the entire genome, optimizing genome editing potential for patients [3]. Event Details - Brian C. Thomas, PhD, CEO and founder of Metagenomi, will present on January 15, 2025, at 4:30 p.m. PT in San Francisco [1]. - A live webcast of the presentation will be available on the company's investor website, with a replay accessible for a limited time [2].

Core Insights - Metagenomi, Inc. is focused on developing curative therapeutics using its proprietary gene editing toolbox, emphasizing the precision and safety of its technologies [1][2][3] Group 1: Gene Editing Technologies - MGX-001, a candidate for hemophilia A, utilizes the MG29-1 nuclease and shows no identifiable off-target editing, confirmed through various assays [2] - The MG29-1 nuclease targeting the albumin safe harbor locus demonstrated no evidence of translocations in primary human hepatocytes [2] - Metagenomi's adenine base editor (ABE) for ex vivo cell therapy showed no detectable translocations and no significant genomic base composition differences in primary T-cells compared to unedited cells [2] Group 2: Company Overview - Metagenomi leverages metagenomics to develop a comprehensive toolbox for genome editing, which includes programmable nucleases, base editors, and integration systems [3] - The company aims to correct any type of genetic mutation found in the genome, utilizing four billion years of microbial evolution [3] - Metagenomi's diverse and modular toolbox is designed to access the entire genome and select optimal tools for effective genome editing [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Metagenomi stock between February 9 and 13, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 25, 2024 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] Group 2: Company Background and Allegations - Metagenomi, described as a "genetic medicines company," had a collaboration with Moderna, which was highlighted during its IPO [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at $15 per share [4] - The collaboration with Moderna was terminated on May 1, 2024, leading to claims that investors suffered damages when the true details were revealed [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Metagenomi stock during the IPO from February 9 to 13, 2024, may be eligible for compensation without any out-of-pocket costs through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 25, 2024 [2][5] - The lawsuit claims that investors suffered damages after Metagenomi announced the termination of its collaboration with Moderna, which was a key aspect of its IPO presentation [4] Group 2: Company Background - Metagenomi is described as a "genetic medicines company" that had a significant collaboration with Moderna, including a Strategic Collaboration and License Agreement established on October 29, 2021 [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [4]

Core Viewpoint - A securities class action lawsuit has been filed against Metagenomi Inc. for allegedly misleading investors regarding its business prospects and relationship with Moderna during the specified Class Period from February 6, 2024, to September 26, 2024 [1]. Company Overview - Metagenomi is a genetic medicines company based in Emeryville, CA, with a significant collaboration with Moderna, a leading Covid-19 vaccine company [3]. - The collaboration included a Strategic Collaboration and License Agreement established on October 29, 2021, which involved multiple four-year research programs [3]. IPO and Stock Performance - Metagenomi completed its initial public offering (IPO) on February 13, 2024, selling 6.25 million shares at $15 per share [4]. - Following the announcement of the termination of the collaboration with Moderna on May 1, 2024, Metagenomi's shares dropped from $7.04 to $6.17 within a day and continued to decline, trading slightly above $2.00 at the time of the lawsuit filing [5].

Core Viewpoint - Metagenomi, Inc. is facing a class action lawsuit following the termination of its collaboration with Moderna, which was a significant aspect of its initial public offering narrative [3]. Group 1: Company Background - Metagenomi, Inc. is characterized as a "genetic medicines company" and had a strategic collaboration with Moderna, a leading Covid-19 vaccine company [3]. - The company completed its initial public offering on February 13, 2024, selling 6.25 million shares at $15 per share [3]. Group 2: Allegations and Impact - The lawsuit alleges that Metagenomi misled investors regarding its collaboration with Moderna, which was critical to its business model [3]. - Following the announcement of the termination of the collaboration on May 1, 2024, Metagenomi's stock price fell from $7.04 to $6.17 within a day, indicating a significant market reaction to the news [3]. Group 3: Legal Proceedings - Shareholders who purchased shares during the class period from February 9 to 13, 2024, are encouraged to register for the class action lawsuit [2][4]. - The deadline for shareholders to seek lead plaintiff status is November 25, 2024 [4].

Core Viewpoint - Metagenomi, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its initial public offering and subsequent termination of a collaboration with Moderna [1][2][3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased shares during Metagenomi's IPO from February 9 to 13, 2024 [2]. - Metagenomi's IPO involved selling 6.25 million shares at a price of $15 per share [3]. - The company claimed a significant partnership with Moderna, which was critical to its business model, but this partnership was terminated on May 1, 2024, leading to a decline in stock price from $7.04 to $6.17 per share [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until November 25, 2024, to request appointment as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Metagenomi To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Metagenomi between February 9, 2024 and September 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Nov. 21, 2024 /P ...

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company’s initial public offering conducted between February 9 and 13, 2024 (the “IPO”), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Metagenomi (MGX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a chang ...